| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Whole Genome Sequencing | 2 | 2019 | 27 | 1.340 |
Why?
|
| MicroRNAs | 6 | 2022 | 82 | 1.320 |
Why?
|
| Genome, Bacterial | 2 | 2019 | 50 | 0.800 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 23 | 0.750 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 15 | 0.700 |
Why?
|
| Drug Resistance, Microbial | 1 | 2019 | 14 | 0.700 |
Why?
|
| Bacteria | 1 | 2019 | 86 | 0.660 |
Why?
|
| Gram-Negative Bacteria | 1 | 2018 | 3 | 0.650 |
Why?
|
| Proteome | 1 | 2018 | 57 | 0.630 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 48 | 0.630 |
Why?
|
| Transcriptome | 5 | 2022 | 201 | 0.630 |
Why?
|
| Models, Statistical | 1 | 2015 | 46 | 0.530 |
Why?
|
| Humans | 14 | 2022 | 4119 | 0.520 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2022 | 552 | 0.420 |
Why?
|
| RNA, Messenger | 3 | 2022 | 263 | 0.320 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2018 | 26 | 0.290 |
Why?
|
| Male | 8 | 2020 | 1811 | 0.280 |
Why?
|
| Finches | 2 | 2017 | 2 | 0.280 |
Why?
|
| Genetics, Population | 2 | 2017 | 46 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 529 | 0.260 |
Why?
|
| Gene Expression Profiling | 5 | 2022 | 345 | 0.260 |
Why?
|
| Genotype | 4 | 2019 | 320 | 0.260 |
Why?
|
| Female | 7 | 2020 | 2147 | 0.250 |
Why?
|
| Phenotype | 3 | 2022 | 479 | 0.230 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 13 | 0.220 |
Why?
|
| Crohn Disease | 1 | 2022 | 16 | 0.220 |
Why?
|
| Axin Protein | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2022 | 4 | 0.210 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 7 | 0.210 |
Why?
|
| Adenoma | 1 | 2022 | 10 | 0.210 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 27 | 0.210 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 42 | 0.210 |
Why?
|
| Aged | 3 | 2020 | 580 | 0.200 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 3 | 0.190 |
Why?
|
| ABO Blood-Group System | 1 | 2020 | 3 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 13 | 0.190 |
Why?
|
| Betacoronavirus | 1 | 2020 | 6 | 0.190 |
Why?
|
| Middle Aged | 3 | 2020 | 843 | 0.190 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 10 | 0.190 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 11 | 0.190 |
Why?
|
| Cloud Computing | 1 | 2020 | 1 | 0.190 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 1 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 8 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2020 | 4 | 0.190 |
Why?
|
| RNA Interference | 2 | 2019 | 48 | 0.180 |
Why?
|
| Acinetobacter baumannii | 1 | 2019 | 2 | 0.180 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 92 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 23 | 0.180 |
Why?
|
| Internet | 1 | 2019 | 19 | 0.170 |
Why?
|
| Paratuberculosis | 1 | 2019 | 1 | 0.170 |
Why?
|
| Mycobacterium avium subsp. paratuberculosis | 1 | 2019 | 1 | 0.170 |
Why?
|
| Cattle Diseases | 1 | 2019 | 2 | 0.170 |
Why?
|
| Animals | 6 | 2022 | 1545 | 0.170 |
Why?
|
| Escherichia coli | 1 | 2019 | 57 | 0.170 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 36 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 210 | 0.160 |
Why?
|
| CpG Islands | 1 | 2018 | 51 | 0.160 |
Why?
|
| Blood Cells | 1 | 2017 | 11 | 0.160 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 28 | 0.160 |
Why?
|
| Young Adult | 2 | 2015 | 345 | 0.160 |
Why?
|
| Macrophages | 1 | 2019 | 124 | 0.150 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2017 | 1 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 3 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 10 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 102 | 0.150 |
Why?
|
| Computational Biology | 2 | 2015 | 164 | 0.150 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 92 | 0.150 |
Why?
|
| Albuterol | 1 | 2016 | 1 | 0.150 |
Why?
|
| Motor Endplate | 1 | 2016 | 1 | 0.150 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2016 | 1 | 0.150 |
Why?
|
| Neuromuscular Junction | 1 | 2016 | 2 | 0.150 |
Why?
|
| Muscular Dystrophies | 1 | 2016 | 3 | 0.150 |
Why?
|
| Desmin | 1 | 2016 | 6 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 7 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2018 | 186 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 90 | 0.140 |
Why?
|
| Support Vector Machine | 1 | 2015 | 1 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 173 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2015 | 62 | 0.130 |
Why?
|
| Inbreeding | 1 | 2015 | 15 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 60 | 0.130 |
Why?
|
| Algorithms | 1 | 2015 | 165 | 0.120 |
Why?
|
| Models, Genetic | 1 | 2015 | 117 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2013 | 1 | 0.120 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2013 | 1 | 0.120 |
Why?
|
| Tacrolimus | 1 | 2013 | 2 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 9 | 0.120 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2013 | 2 | 0.120 |
Why?
|
| Demyelinating Diseases | 1 | 2013 | 5 | 0.120 |
Why?
|
| Genomics | 3 | 2022 | 143 | 0.120 |
Why?
|
| Adult | 1 | 2015 | 944 | 0.120 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 417 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 111 | 0.090 |
Why?
|
| Haplotypes | 2 | 2022 | 122 | 0.090 |
Why?
|
| Mice | 2 | 2022 | 737 | 0.080 |
Why?
|
| Gene Expression | 2 | 2018 | 138 | 0.070 |
Why?
|
| Adolescent | 2 | 2018 | 493 | 0.070 |
Why?
|
| Child | 2 | 2018 | 557 | 0.070 |
Why?
|
| Pedigree | 2 | 2016 | 304 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2017 | 138 | 0.060 |
Why?
|
| Neutrophil Activation | 1 | 2022 | 4 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2022 | 68 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2022 | 5 | 0.050 |
Why?
|
| Caco-2 Cells | 1 | 2022 | 6 | 0.050 |
Why?
|
| Colon | 1 | 2022 | 8 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 17 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2022 | 38 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 161 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2022 | 70 | 0.050 |
Why?
|
| Mutation | 2 | 2015 | 608 | 0.050 |
Why?
|
| Alleles | 1 | 2022 | 221 | 0.050 |
Why?
|
| Spain | 1 | 2020 | 4 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 11 | 0.050 |
Why?
|
| Italy | 1 | 2020 | 32 | 0.050 |
Why?
|
| Multigene Family | 1 | 2020 | 30 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 25 | 0.050 |
Why?
|
| European Union | 1 | 2020 | 1 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2020 | 3 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2020 | 120 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2020 | 322 | 0.040 |
Why?
|
| Cattle | 1 | 2019 | 22 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 31 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 133 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2017 | 8 | 0.040 |
Why?
|
| Exosomes | 1 | 2017 | 7 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2017 | 17 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 60 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2017 | 42 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2017 | 31 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 90 | 0.040 |
Why?
|
| Consanguinity | 1 | 2016 | 56 | 0.040 |
Why?
|
| Genes, Recessive | 1 | 2016 | 44 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2017 | 146 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 143 | 0.030 |
Why?
|
| Immunoglobulin Light Chains, Surrogate | 1 | 2015 | 2 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 11 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 12 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 15 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 17 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 33 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 29 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2015 | 15 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 51 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 122 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2015 | 191 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 122 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 77 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
| Transfection | 1 | 2013 | 51 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 249 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 55 | 0.030 |
Why?
|
